Prostacyclin mediates neuropathic pain through interleukin 1β-expressing resident macrophages

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Prostacyclin is a key mediator of peripheral pain sensation.
• Neuropathic pain involves complex inflammatory and cellular signaling pathways.
• The role of prostacyclin and its receptor (IP) in neuropathic pain remains to be fully elucidated.

Purpose of the Study:

• To investigate the role of prostacyclin receptor (IP) in mediating neuropathic pain.
• To identify the cellular mechanisms underlying IP's contribution to pain signaling.
• To explore potential therapeutic targets for neuropathic pain management.

Main Methods:

• Utilized prostacyclin receptor (IP) knockout mice and selective IP deficiency in myeloid cells.
• Administered IP antagonists and agonists, as well as IL-1 receptor antagonist (anakinra).
• Employed in vitro and in vivo models of nerve injury and pain behavior assessment, including immunohistochemistry and cytokine analysis.

Main Results:

• IP knockout mice exhibited significantly reduced neuropathic pain behavior.
• IP deficiency in myeloid cells or blockade at the injury site mimicked these antinociceptive effects.
• IP was found on resident macrophages expressing IL-1β at nerve injury sites.
• IP activation promoted macrophage accumulation and IL-1β expression, contributing to pain.
• IL-1 receptor antagonism reduced pain in wild-type but not IP knockout mice.
• Early, continuous cyclooxygenase inhibition decreased pain and macrophage infiltration.

Conclusions:

• Early prostacyclin synthesis at the injury site drives neuropathic pain.
• This process involves the accumulation of IL-1β-expressing macrophages mediated by IP signaling.
• Targeting the prostacyclin pathway and associated macrophage accumulation offers a promising therapeutic strategy for neuropathic pain.